Skip to content
Back to TNDM

Tandem Diabetes Care Inc

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
3
Purchases
0
Sales
3
Purchase value
$0.00
Sale value
$36.91K

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Christopher J TwomeyDirector
4Rule 10b5-1 plan disclosed
Filed Oct 29, 2026Period of report Oct 27, 20260001438133-26-000136
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 27, 2026
Common StockF21,700$19.15$32.56K24,434Direct
Filing footnotes · 7
  1. F1Represents shares of common stock received upon exercise of a stock option award.
  2. F2The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2026.
  3. F3The securities are directly owned by Twomey Family Investments, LLC. The Reporting Person is co-manager of Twomey Family Investments, LLC and shares voting and investment power over these securities held by Twomey Family Investments, LLC and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Twomey Family Investments, LLC, except to the extent of his proportionate pecuniary interest therein.
  4. F4The securities are held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002.
  5. F5Awarded on November 15, 2016 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto.
  6. F6Such options became exercisable in 12 equal monthly installments beginning on December 15, 2016.
  7. F7Such options expire on November 15, 2026.
Open on SEC EDGAR
Mark David NovaraEVP & CHIEF COMMERCIAL OFFICER
4
Filed Mar 18, 2026Period of report Mar 16, 20260001438133-26-000023
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 17, 2026
Common StockF2187$23.05$4.31K37,656Direct
Filing footnotes · 5
  1. F1Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
  2. F2The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2025.
  3. F3Awarded on December 15, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
  4. F4Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
  5. F5RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.
Open on SEC EDGAR
Mark David NovaraEVP & CHIEF COMMERCIAL OFFICER
4Rule 10b5-1 plan disclosed
Filed Mar 9, 2026Period of report Mar 5, 20260001438133-26-000022
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 5, 2026
Common StockF12$22.81$45.6235,969Direct
Filing footnotes · 1
  1. F1The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2025.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.